
July 1 (Reuters) - Cognition Therapeutics Inc CGTX.O:
COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE SURPASSES 50% ENROLLMENT TARGET
COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE SURPASSES 50% ENROLLMENT TARGET
COGNITION THERAPEUTICS INC - PHASE 2 SHINE STUDY SHOWS 38% SLOWING OF COGNITIVE DECLINE WITH ZERVIMESINE
COGNITION THERAPEUTICS INC - LOWER P-TAU217 LEVELS SHOW 95% SLOWING OF COGNITIVE DECLINE WITH ZERVIMESINE
COGNITION THERAPEUTICS INC - START STUDY RECEIVES $81 MILLION GRANT SUPPORT FROM NIA